- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Transport maximum.
Displaying page 1 of 2.
EudraCT Number: 2015-005727-80 | Sponsor Protocol Number: EMPA | Start Date*: Information not available in EudraCT |
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||
Full Title: Effect of insulin on renal maximum glucose transport capacity: interaction with empagliflozin. A not randomized pilot study. | ||
Medical condition: Patients with diabetes mellitus type 2 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006693-24 | Sponsor Protocol Number: Moli1901-010B | Start Date*: 2007-05-09 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis | |||||||||||||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) FR (Completed) DE (Completed) HU (Completed) SE (Completed) ES (Completed) PL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004835-26 | Sponsor Protocol Number: D169AL00005 | Start Date*: 2021-05-24 | |||||||||||
Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST | |||||||||||||
Full Title: Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubuloi... | |||||||||||||
Medical condition: Chronic Kidney Deseas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000447-27 | Sponsor Protocol Number: USKH_VL1 | Start Date*: 2012-07-25 |
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel | ||
Full Title: Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery | ||
Medical condition: Pharmacokinetic trial in patients, with a good general condition before standard abdominal surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001589-17 | Sponsor Protocol Number: KN 38-7271-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:KeyNeurotek Pharmaceuticals AG | ||
Full Title: A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic b... | ||
Medical condition: Comatose patients with traumatic brain injury (TBI). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000993-32 | Sponsor Protocol Number: S55300 | Start Date*: 2013-05-07 | ||||||||||||||||
Sponsor Name:University Hospital Leuven | ||||||||||||||||||
Full Title: Does prolonged GnRH downregulation prior to ART improve the clinical pregnancy rate in postoperative endometriosis patients? A RCT | ||||||||||||||||||
Medical condition: endometriosis, subfertility | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001517-32 | Sponsor Protocol Number: K-877-201 | Start Date*: 2013-10-02 | |||||||||||
Sponsor Name:Kowa Research Europe | |||||||||||||
Full Title: A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels | |||||||||||||
Medical condition: dyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003664-25 | Sponsor Protocol Number: 11323 | Start Date*: 2023-12-21 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: The impact of gender differences in P-glycoprotein function measured with [18F]MC225 and PET | ||
Medical condition: Gender, healthy volunteers | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000630-17 | Sponsor Protocol Number: MER-XMT-1536-1 | Start Date*: 2021-09-21 | ||||||||||||||||
Sponsor Name:Mersana Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b | ||||||||||||||||||
Medical condition: High grade serous ovarian cancer or non-small cell lung cancer (NSCLC), adenocarcinoma subtype | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) NO (Completed) LT (Completed) CZ (Completed) HU (Completed) BG (Completed) FI (Completed) PL (Completed) DK (Completed) IT (Completed) AT (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002117-36 | Sponsor Protocol Number: CT-CL02 | Start Date*: 2018-11-28 | |||||||||||
Sponsor Name:Cristal Therapeutics | |||||||||||||
Full Title: A Phase IIa Exploratory Study of CriPec® docetaxel Monotherapy in Subjects with Platinum Resistant Ovarian Cancer. | |||||||||||||
Medical condition: Platinum Resistant Ovarian Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000201-72 | Sponsor Protocol Number: 1 | Start Date*: 2012-05-11 |
Sponsor Name:University of Aberdeen [...] | ||
Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease | ||
Medical condition: Peripheral arterial Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003297-53 | Sponsor Protocol Number: 18748 | Start Date*: 2020-10-15 | ||||||||||||||||
Sponsor Name:Bayer AG | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of individually titrated oral doses of runcaciguat in subjects with clinical diagnosis of chroni... | ||||||||||||||||||
Medical condition: Treatment of cardiovascular and renal disease in patients with chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) DK (Completed) IT (Completed) FI (Completed) SE (Completed) ES (Completed) PL (Completed) AT (Completed) BE (Completed) BG (Completed) SK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005949-38 | Sponsor Protocol Number: M10-265 | Start Date*: 2008-09-29 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastat... | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) CZ (Completed) BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002560-34 | Sponsor Protocol Number: F1J-US-HMFR(b) | Start Date*: 2008-09-02 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis | |||||||||||||
Medical condition: Central neuropathic pain due to Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001724-19 | Sponsor Protocol Number: 2013/2 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
Full Title: Pilot study to assess P-glycoprotein function at the blood-brain barrier of patients with mild to moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer's disease and healthy controls (2 groups: 1 group with young healthy volunteers, 1 group with elderly healthy volunteers) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001435-63 | Sponsor Protocol Number: NACFL-ZI-L-01-06 | Start Date*: 2008-01-28 | |||||||||||
Sponsor Name:ZAMBON ITALIA | |||||||||||||
Full Title: AEROSOLIC TREATMENT OF ACUTE AND RECURRENT RHINOSINUSITIS DURING INTERCRITICAL STAGES : SINGLE BLIND CLINICAL STUDY, N-ACETYLCISTEIN VS AMBROXOL, ASSOCIATED WITH CORTISONE THERAPY | |||||||||||||
Medical condition: Patients with acute recurrent rhinosinusitis(intercritical stages) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005531-13 | Sponsor Protocol Number: MED3-201401 | Start Date*: 2015-11-26 |
Sponsor Name:Univerity of Bonn | ||
Full Title: Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, ... | ||
Medical condition: Chronic Phase Chronic myelogenous leukaemia( CP-CML) patients who either developed intolerance or treatment failure to previous Imatinib, Dasatinib or Nilotinib as 1st or 2nd line therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-000202-37 | Sponsor Protocol Number: BUR02 | Start Date*: 2018-10-09 | |||||||||||
Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd | |||||||||||||
Full Title: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burn... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005696-24 | Sponsor Protocol Number: MS200095-0022 | Start Date*: 2016-07-04 |
Sponsor Name:Merck KGaA | ||
Full Title: A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (V... | ||
Medical condition: Advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) AT (Completed) NL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001835-35 | Sponsor Protocol Number: 2014.TTRANSPORT | Start Date*: 2015-03-30 | |||||||||||
Sponsor Name:Fundación Santiago Dexeus Font (Dexeus) | |||||||||||||
Full Title: Transdermal testosterone gel for poor ovarian responders. A multicenter double-blind placebo controlled randomized trial. | |||||||||||||
Medical condition: Infertility in women with poor ovarian response to stimulation for IVF/ICSI | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
